Syngene Q1 FY27 Revenue Down 16% to ₹736 Cr; EBITDA Drops 56%

Syngene International Ltd reported its Q1 FY27 results, with revenue from operations at ₹736 Cr, a 16% decrease year-on-year from ₹875 Cr in Q1 FY26. Operating EBITDA saw a significant drop of 56% to ₹91 Cr from ₹206 Cr. The company cited a lack of offtake from a major biologics client and forex hedge loss as primary reasons for the performance dip. Profit After Tax (PAT) before exceptional items was ₹11 Cr, down 99% from ₹87 Cr. The company announced strategic shifts with Kiran Mazumdar-Shaw taking on the role of Executive Chairperson and Siddharth Mittal as the new MD & CEO. They aim to focus on CDMO and AI-led services for sustainable growth. The company also announced board changes with Dr. Vijaya Chandru and Dr. Arun Chandavarkar appointed as Independent Directors, while Dr. Kush Parmar steps down. Syngene also signed an MoU with THSTI for clinical development and translational research.